Official Title
18F-αvβ6-binding-peptide PET/CT in Patients Post SARS CoV2 Infection
Brief Summary

This is a PET/CT study using the 18F-αvβ6-binding-peptide.The goal of this study is to evaluate this peptide in patients after infection with SARS CoV2.

Detailed Description

The goal of the study is to to acquire 18F-αvβ6-BP PET/CT images in patients diagnosed with
SARS CoV2 and to demonstrate the ability of 18F-αvβ6-BP to detect lung damage.

Enrolling by invitation
SARS-CoV-2 Infection

Drug: 18F-αvβ6-BP

Subjects will be injected once per imaging session (a maximum of 3 imaging sessions) with up to 10 mCi (±20%) of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 secs).

Eligibility Criteria

Inclusion Criteria:

- Men and women age ≥ 18 yrs

- Diagnosed with SARS CoV2

- Must have 2 sequential COVID negative tests prior to each scan

- Must have no previous lung disease prior to SARS CoV2 infection

- Lung image (Xray or CT) taken during infectious/ diagnosis period

- Will sign the IRB-approved consent form

- Able to remain motionless for up to 30-60 minutes per scan.

Exclusion Criteria:

- Life expectancy <3 mo

- Women who are pregnant or breast-feeding

- Patients who cannot undergo PET/CT scanning because of weight limits(>350lbs)

- Lack of availability for follow-up assessments

- Re-infection with SARS CoV2 between scan sessions

- Other active infectious respiratory illness

Eligibility Gender
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
United States

University of California Davis
Sacramento, California, United States

University of California, Davis
NCT Number
COVID-19; SARS-CoV2 infection
MeSH Terms